Finally, we demonstrate that the investigated MIR149, MIR605, MIR938, DROSHA, MIR200C, MIR499A, MIRLET7A1, MIR323B, and MIR2053 could potentially modulate the therapeutic response of standard treatment for ALL. This evidence concerns the gene MIR605 and acute lymphoblastic leukemia.